Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer
Vandana Singh 12 hours ago
Trading IdeasMoversNewsGeneralBiotechTop StoriesHealth CareLarge Cap
Merck's Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary overall survival endpoint in advanced gastroesophageal cancer.
Merck & Co. Inc. (NYSE:MRK) on Friday announced that its pivotal Phase 3 TroFuse-015 trial met its primary endpoint of overall survival (OS).
Evaluating sacituzumab tirumotecan (sac-TMT), the trial marks the first time a TROP2-directed ADC improved OS in a global Phase 3 study for locally advanced unresectable or metastatic gastroesophageal adenocarcinoma patients who received two or more prior lines of systemic therapy.
sac-TMT is an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech.
Trial Efficacy And Safety Results
At final analysis, sac-TMT delivered a statistically significant and clinically meaningful OS improvement compared to treatment of physician’s choice (TPC), which consisted of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel.
Researchers observed generally consistent results across patient subgroups regardless of TROP2 expression status.
However, sac-TMT did not meet its secondary endpoint of progression-free survival (PFS).
Although the therapy demonstrated a nominally improved benefit in objective response rate (ORR) favoring sac-TMT over TPC, investigators did not formally test this secondary endpoint under the prespecified analysis plan.
The therapy maintained a safety profile consistent with previously reported sac-TMT studies, revealing no new safety signals.
Expanding TroFuse Clinical Program
TroFuse-015 marks the second positive Phase 3 study from Merck’s global TroFuse clinical development program for sac-TMT.
The program currently comprises 18 ongoing global Phase 3 trials across multiple tumor types, representing the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date.
Merck is evaluating sac-TMT as both a monotherapy and in combination with immunotherapies spanning early-to-late-stage disease.
The studies cover endometrial, bladder, breast, cervical, gastric, non-small cell lung, and ovarian cancers, with 14 of the 18 Phase 3 studies—including TroFuse-015.
MRK Price Action: Merck & Co shares were up 2.07% at $135.56 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock
More on MRK
Benzinga
Merck's Pivotal Phase 3 Trofuse-015 Trial Meets Primary Endpoint Of Overall Survival In Pretreated Gastroesophageal AdenocarcinomaSac-TMT is the first TROP2 ADC to improve OS compared to treatment of physician’s choice (TPC) in patients with advanced gastroesophageal adenocarcinoma who have received two or more prior lines of…
